Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective
Purpose. To evaluate the cost-effectiveness of denosumab versus other osteoporotic treatments in older men with osteoporosis from a US payer perspective. Methods. A lifetime cohort Markov model previously developed for postmenopausal osteoporosis (PMO) was used. Men in the model were 78 years old,...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Osteoporosis |
| Online Access: | http://dx.doi.org/10.1155/2015/627631 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850157777695014912 |
|---|---|
| author | Stuart Silverman Irene Agodoa Morgan Kruse Anju Parthan Eric Orwoll |
| author_facet | Stuart Silverman Irene Agodoa Morgan Kruse Anju Parthan Eric Orwoll |
| author_sort | Stuart Silverman |
| collection | DOAJ |
| description | Purpose. To evaluate the cost-effectiveness of denosumab versus other osteoporotic treatments in older men with osteoporosis from a US payer perspective. Methods. A lifetime cohort Markov model previously developed for postmenopausal osteoporosis (PMO) was used. Men in the model were 78 years old, with a BMD T-score of −2.12 and a vertebral fracture prevalence of 23%. During each 6-month Markov cycle, patients could have experienced a hip, vertebral or nonhip, nonvertebral (NHNV) osteoporotic fracture, remained in a nonfracture state, remained in a postfracture state, or died. Background fracture risks, mortality rates, persistence rates, health utilities, and medical and drug costs were derived from published sources. Previous PMO studies were used for drug efficacy in reducing fracture risk. Lifetime expected costs and quality-adjusted life-years (QALYs) were estimated for denosumab, generic alendronate, risedronate, ibandronate, teriparatide, and zoledronate. Results. Denosumab had an incremental cost-effectiveness ratio (ICER) of $16,888 compared to generic alendronate and dominated all other treatments. Results were most sensitive to changes in costs of denosumab and the relative risk of hip fracture. Conclusion. Despite a higher annual treatment cost compared to other medications, denosumab is cost-effective compared to other osteoporotic treatments in older osteoporotic US men. |
| format | Article |
| id | doaj-art-2c819bd5149945ddbd854ee449e187e9 |
| institution | OA Journals |
| issn | 2090-8059 2042-0064 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Osteoporosis |
| spelling | doaj-art-2c819bd5149945ddbd854ee449e187e92025-08-20T02:24:04ZengWileyJournal of Osteoporosis2090-80592042-00642015-01-01201510.1155/2015/627631627631Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer PerspectiveStuart Silverman0Irene Agodoa1Morgan Kruse2Anju Parthan3Eric Orwoll4Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USAAmgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USAOptum, 950 Winter Street, Suite 2800, Waltham, MA 02451, USAOptum, 950 Winter Street, Suite 2800, Waltham, MA 02451, USAOregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USAPurpose. To evaluate the cost-effectiveness of denosumab versus other osteoporotic treatments in older men with osteoporosis from a US payer perspective. Methods. A lifetime cohort Markov model previously developed for postmenopausal osteoporosis (PMO) was used. Men in the model were 78 years old, with a BMD T-score of −2.12 and a vertebral fracture prevalence of 23%. During each 6-month Markov cycle, patients could have experienced a hip, vertebral or nonhip, nonvertebral (NHNV) osteoporotic fracture, remained in a nonfracture state, remained in a postfracture state, or died. Background fracture risks, mortality rates, persistence rates, health utilities, and medical and drug costs were derived from published sources. Previous PMO studies were used for drug efficacy in reducing fracture risk. Lifetime expected costs and quality-adjusted life-years (QALYs) were estimated for denosumab, generic alendronate, risedronate, ibandronate, teriparatide, and zoledronate. Results. Denosumab had an incremental cost-effectiveness ratio (ICER) of $16,888 compared to generic alendronate and dominated all other treatments. Results were most sensitive to changes in costs of denosumab and the relative risk of hip fracture. Conclusion. Despite a higher annual treatment cost compared to other medications, denosumab is cost-effective compared to other osteoporotic treatments in older osteoporotic US men.http://dx.doi.org/10.1155/2015/627631 |
| spellingShingle | Stuart Silverman Irene Agodoa Morgan Kruse Anju Parthan Eric Orwoll Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective Journal of Osteoporosis |
| title | Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective |
| title_full | Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective |
| title_fullStr | Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective |
| title_full_unstemmed | Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective |
| title_short | Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective |
| title_sort | denosumab for elderly men with osteoporosis a cost effectiveness analysis from the us payer perspective |
| url | http://dx.doi.org/10.1155/2015/627631 |
| work_keys_str_mv | AT stuartsilverman denosumabforelderlymenwithosteoporosisacosteffectivenessanalysisfromtheuspayerperspective AT ireneagodoa denosumabforelderlymenwithosteoporosisacosteffectivenessanalysisfromtheuspayerperspective AT morgankruse denosumabforelderlymenwithosteoporosisacosteffectivenessanalysisfromtheuspayerperspective AT anjuparthan denosumabforelderlymenwithosteoporosisacosteffectivenessanalysisfromtheuspayerperspective AT ericorwoll denosumabforelderlymenwithosteoporosisacosteffectivenessanalysisfromtheuspayerperspective |